TXG
VENTE TOTALE: 72 607 titres (~4 422 831,38 $ US)
- Insiders
- Saxonov Serge, Hindson Benjamin J., SULIMAN SHEHNAAZ, Teichmann Sarah A., STUELPNAGEL JOHN R
- Total bought
- —
- Total sold
- $4,422,831
- Last activity
- 2026-08-26
- Last synced
-
2026-09-01 10:09:45
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bullish signal Scored 2026-08-31
TXG presents a moderately compelling setup combining solid liquidity (85) with a meaningful earnings catalyst — a Q2 beat, raised 2026 guidance, and a patent verdict win — though the catalyst confidence of 0.7 and a…
The first sentence of the analysis written for TXG on 2026-08-31 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 69.1% | 67.9% | 66.2% | 76.7% | 84.9% | |
| Ebit Margin | -6.2% | -29.1% | -40.2% | -31.3% | -10.8% | |
| Ebitda Margin | 0.6% | -21.9% | -33.2% | -24.9% | -5.0% | |
| Operating Profit Margin | -17.2% | -31.9% | -42.9% | -32.5% | -10.8% | |
| Pretax Profit Margin | -6.2% | -29.1% | -40.2% | -31.4% | -11.0% | |
| Continuous Operations Profit Margin | -6.8% | -29.9% | -41.2% | -32.1% | -11.9% | |
| Net Profit Margin | -6.8% | -29.9% | -41.2% | -32.1% | -11.9% | |
| Bottom Line Profit Margin | -6.8% | -29.9% | -41.2% | -32.1% | -11.9% | |
| Current Ratio | 4.460 | 4.968 | 4.687 | 4.849 | 6.774 | |
| Quick Ratio | 4.093 | 4.261 | 4.107 | 4.226 | 6.231 | |
| Solvency Ratio | 0.001 | -0.666 | -0.944 | -0.596 | -0.149 | |
| Cash Ratio | 3.089 | 2.925 | 2.825 | 1.678 | 5.323 | |
| Price To Earnings Ratio | -46.600 | -9.447 | -25.670 | -24.959 | -281.057 | |
| Price To Earnings Growth Ratio | 0.605 | 0.312 | -0.521 | -0.142 | 3.118 | |
| Forward Price To Earnings Growth Ratio | 0.605 | 0.312 | -0.521 | -0.142 | 3.118 | |
| Price To Earnings Diluted Ratio | -46.600 | -9.447 | -25.670 | -24.959 | -281.057 | |
| Price To Earnings Diluted Growth Ratio | 0.605 | 0.312 | -0.521 | -0.142 | 3.118 | |
| Price To Book Ratio | 2.555 | 2.436 | 8.848 | 5.149 | 20.105 | |
| Price To Sales Ratio | 3.165 | 2.832 | 10.597 | 8.034 | 33.512 | |
| Price To Free Cash Flow Ratio | 15.637 | -301.917 | -101.305 | -25.105 | -134.018 | |
| Price To Operating Cash Flow Ratio | 14.955 | 259.556 | -431.437 | -123.460 | -769.074 | |
| Debt To Assets Ratio | 0.151 | 0.090 | 0.099 | 0.092 | 0.080 | |
| Debt To Equity Ratio | 0.198 | 0.116 | 0.129 | 0.118 | 0.100 | |
| Debt To Capital Ratio | 0.165 | 0.104 | 0.114 | 0.106 | 0.091 | |
| Long Term Debt To Capital Ratio | 0.084 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.308 | 1.294 | 1.302 | 1.277 | 1.246 | |
| Working Capital Turnover Ratio | 1.289 | 1.306 | 1.272 | 0.905 | 0.758 | |
| Operating Cash Flow Ratio | 0.887 | 0.057 | -0.120 | -0.257 | -0.194 | |
| Operating Cash Flow Sales Ratio | 0.212 | 0.011 | -0.025 | -0.065 | -0.044 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.956 | -0.860 | 4.259 | 4.918 | 5.739 | |
| Debt Service Coverage Ratio | 0.025 | -34,728.750 | -6,407.485 | -278.399 | -33.606 | |
| Interest Coverage Ratio | 0.000 | -48,639.750 | -8,040.273 | -352.824 | -61.100 | |
| Short Term Operating Cash Flow Coverage Ratio | 12.385 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.863 | 0.081 | -0.159 | -0.353 | -0.261 | |
| Capital Expenditure Coverage Ratio | 22.923 | 0.538 | -0.307 | -0.255 | -0.211 | |
| Dividend Paid And Capex Coverage Ratio | 22.923 | 0.538 | -0.307 | -0.255 | -0.211 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 439.612 | -10.958 | -30.679 | -31.321 | -647.772 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 69.0% | ▲1.2% | ▼-3.9% |
| Ebit Margin | -6.2% | ▲22.9% | ▲17.3% |
| Ebitda Margin | 0.6% | ▲22.6% | ▲17.5% |
| Operating Profit Margin | -17.2% | ▲14.6% | ▲9.8% |
| Pretax Profit Margin | -6.2% | ▲22.9% | ▲17.4% |
| Continuous Operations Profit Margin | -6.8% | ▲23.1% | ▲17.6% |
| Net Profit Margin | -6.8% | ▲23.1% | ▲17.6% |
| Bottom Line Profit Margin | -6.8% | ▲23.1% | ▲17.6% |
| Current Ratio | 4.460 | ▼-0.508 | ▼-0.688 |
| Quick Ratio | 4.093 | ▼-0.168 | ▼-0.491 |
| Solvency Ratio | 0.001 | ▲0.667 | ▲0.472 |
| Cash Ratio | 3.089 | ▲0.164 | ▼-0.079 |
| Price To Earnings Ratio | -46.600 | ▼-37.153 | ▲30.947 |
| Price To Earnings Growth Ratio | 0.605 | ▲0.293 | ▼-0.069 |
| Forward Price To Earnings Growth Ratio | 0.605 | ▲0.293 | ▼-0.069 |
| Price To Earnings Diluted Ratio | -46.600 | ▼-37.153 | ▲30.947 |
| Price To Earnings Diluted Growth Ratio | 0.605 | ▲0.293 | ▼-0.069 |
| Price To Book Ratio | 2.555 | ▲0.119 | ▼-5.263 |
| Price To Sales Ratio | 3.165 | ▲0.333 | ▼-8.463 |
| Price To Free Cash Flow Ratio | 15.637 | ▲317.555 | ▲124.979 |
| Price To Operating Cash Flow Ratio | 14.955 | ▼-244.601 | ▲224.847 |
| Debt To Assets Ratio | 0.151 | ▲0.061 | ▲0.049 |
| Debt To Equity Ratio | 0.198 | ▲0.082 | ▲0.066 |
| Debt To Capital Ratio | 0.165 | ▲0.061 | ▲0.049 |
| Long Term Debt To Capital Ratio | 0.084 | ▲0.084 | ▲0.068 |
| Financial Leverage Ratio | 1.308 | ▲0.014 | ▲0.022 |
| Working Capital Turnover Ratio | 1.288 | ▼-0.017 | ▲0.183 |
| Operating Cash Flow Ratio | 0.887 | ▲0.830 | ▲0.812 |
| Operating Cash Flow Sales Ratio | 0.212 | ▲0.201 | ▲0.194 |
| Free Cash Flow Operating Cash Flow Ratio | 0.956 | ▲1.816 | ▼-2.046 |
| Debt Service Coverage Ratio | 0.025 | ▲34728.775 | ▲8289.668 |
| Interest Coverage Ratio | 0.000 | ▲48639.750 | ▲11418.789 |
| Short Term Operating Cash Flow Coverage Ratio | 12.385 | ▲12.385 | ▲9.908 |
| Operating Cash Flow Coverage Ratio | 0.863 | ▲0.782 | ▲0.829 |
| Capital Expenditure Coverage Ratio | 22.923 | ▲22.386 | ▲18.386 |
| Dividend Paid And Capex Coverage Ratio | 22.923 | ▲22.386 | ▲18.386 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 439.612 | ▲450.570 | ▲495.835 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.03B | $1.73B | $6.56B | $4.15B | $16.44B | |
| Enterprise value | $1.72B | $1.47B | $6.29B | $4.02B | $15.93B | |
| EV / Sales | 2.67x | 2.40x | 10.17x | 7.79x | 32.48x | |
| EV / Op. cash flow | 12.63x | 220.32x | -414.07x | -119.75x | -745.42x | |
| EV / Free cash flow | 13.21x | -256.28x | -97.23x | -24.35x | -129.90x | |
| EV / EBITDA | 439.61x | -10.96x | -30.68x | -31.32x | -647.77x | |
| Net debt / EBITDA | -80.90x | 1.95x | 1.29x | 0.97x | 20.55x | |
| Current ratio | 4.46x | 4.97x | 4.69x | 4.85x | 6.77x | |
| Income quality | -3.12x | -0.04x | 0.06x | 0.20x | 0.37x | |
| Graham net-net | $3 | $2 | $2 | $3 | $4 | |
| Tax burden | 109.1% | 102.8% | 102.5% | 102.5% | 108.4% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.3% | 101.6% | |
| Working capital | $531.0M | $466.8M | $468.9M | $504.1M | $637.2M | |
| Invested capital | $885.0M | $796.9M | $834.9M | $890.7M | $897.6M | |
| Return on assets | -4.2% | -19.9% | -26.4% | -16.1% | -5.7% | |
| Operating ROA | -11.3% | -20.7% | -26.6% | -16.4% | -5.4% | |
| Return on tangible assets | -4.5% | -20.3% | -27.0% | -16.6% | -5.9% | |
| Return on equity | -5.5% | -25.7% | -34.4% | -20.6% | -7.1% | |
| Return on invested capital | -12.3% | -24.0% | -31.2% | -18.5% | -5.8% | |
| Return on capital employed | -12.5% | -24.3% | -31.7% | -18.7% | -5.8% | |
| Earnings yield | -2.1% | -10.6% | -3.9% | -4.0% | -0.4% | |
| Free cash flow yield | 6.4% | -0.3% | -1.0% | -4.0% | -0.7% | |
| Capex / Op. cash flow | 4.4% | 186.0% | -325.9% | -391.8% | -473.9% | |
| Capex / Depreciation | 13.5% | 28.4% | 113.5% | 398.9% | 358.5% | |
| Capex / Sales | 0.9% | 2.0% | 8.0% | 25.5% | 20.6% | |
| SG&A / Sales | 49.2% | 56.4% | 55.5% | 57.8% | 52.5% | |
| R&D / Sales | 37.1% | 43.3% | 43.7% | 51.4% | 43.2% | |
| Stock comp / Sales | 17.0% | 23.0% | 27.0% | 26.5% | 19.6% | |
| Intangibles / Total assets | 6.4% | 2.2% | 2.2% | 2.7% | 2.9% | |
| Days sales outstanding | 47d | 53d | 68d | 74d | 63d | |
| Days payables outstanding | 23d | 24d | 27d | 65d | 85d | |
| Operating cycle | 150d | 207d | 196d | 321d | 359d | |
| Cash conversion cycle | 127d | 183d | 169d | 256d | 273d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+17.6%EV / Sales ▲+11.2%EV / EBITDA ▲+4111.8%EV / Op. cash flow ▼-207.692Earnings yield ▲+0.084
Profitability
Return on equity ▲+0.202Return on assets ▲+0.157Return on invested capital ▲+0.117Return on capital employed ▲+0.118Operating ROA ▲+0.093Income quality ▼-3.088Tax burden ▲+0.063
Efficiency
Days sales outstanding ▼-5.665Days payables outstanding ▼-0.641Operating cycle ▼-56.823Cash conversion cycle ▼-56.182Capex / Sales ▼-0.011R&D / Sales ▼-0.062
Balance-sheet strength
Current ratio ▼-0.508Net debt / EBITDA ▼-82.849Working capital ▲+64243000.000Invested capital ▲+88124000.000Intangibles / Total assets ▲+0.042
Change over 5 years
Valuation
Market cap ▼-87.6%EV / Sales ▼-91.8%EV / EBITDA ▲+167.9%EV / Op. cash flow ▲+758.056Earnings yield ▼-0.018
Profitability
Return on equity ▲+0.017Return on assets ▲+0.015Return on invested capital ▼-0.065Return on capital employed ▼-0.067Operating ROA ▼-0.059Income quality ▼-3.492Tax burden ▲+0.007
Efficiency
Days sales outstanding ▼-16.602Days payables outstanding ▼-62.116Operating cycle ▼-208.648Cash conversion cycle ▼-146.532Capex / Sales ▼-0.197R&D / Sales ▼-0.060
Balance-sheet strength
Current ratio ▼-2.314Net debt / EBITDA ▼-101.449Working capital ▼-106237000.000Invested capital ▼-12554000.000Intangibles / Total assets ▲+0.035
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-31 TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences 10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.
- 2026-08-28 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences PR Newswire PLEASANTON, Calif., Aug. 28, 2
- 2026-08-28 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences Jury finds Parse willfully infringed Scale Biosciences'' patents and rejects Parse''s invalidity challenge PLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (NYSE: QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics since 2025.
- 2026-08-20 10x Genomics: The Turnaround Is Real, But Atera Now Has To Deliver (Rating Upgrade) Atera could meaningfully boost instrument sales in late 2026 and drive recurring high-margin consumables revenue from 2027 onward. TXG''s valuation already prices in significant Atera success, but the risk/reward remains skewed to the upside with favorable chart dynamics. Key risks include Atera manufacturing constraints, potential cannibalization of Xenium, rising competition, and ongoing share dilution.
- 2026-08-13 First Trust Advisors LP Invests $271,000 in 10x Genomics $TXG First Trust Advisors LP bought a new stake in 10x Genomics (NASDAQ: TXG) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 12,759 shares of the company''s stock, valued at approximately $271,000. Several other large investors have also modified their holdings
- 2026-08-07 10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up TXG beats Q2 earnings and revenue estimates, expands gross margin and raises its 2026 revenue outlook despite a year-over-year sales decline.
- 2026-08-07 10x Genomics Q2 Earnings Call Highlights 10x Genomics NASDAQ: TXG reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara. Excluding non-recurring settlement revenue in both periods, revenue was $149.4 million, up 3% from a year earlier.
- 2026-08-06 10x Genomics, Inc. (TXG) Q2 2026 Earnings Call Transcript 10x Genomics, Inc. (TXG) Q2 2026 Earnings Call Transcript
- 2026-08-06 10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 2026-08-06 10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates 10x Genomics (TXG) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.28 per share a year ago.